Literature DB >> 7843178

In vitro development and stability of tolerance to cloxacillin and vancomycin in Staphylococcus aureus.

G P Voorn1, J Thompson, W H Goessens, W C Schmal-Bauer, P H Broeders, M F Michel.   

Abstract

The stability of tolerance of Staphylococcus aureus during subculturing at 37 degrees C and development of this property after repeated exposure to cloxacillin or vancomycin were investigated in vitro. Four of five tolerant strains lost this property during repeated subculturing at 37 degrees C for 50 days. Conversely, tolerance emerged in two of four nontolerant strains after repeated cycles of exposure to 25 micrograms of cloxacillin/ml or 10 micrograms of vancomycin/ml alternating with growth in antibiotic-free medium. Previous in vivo exposure to cloxacillin did not enhance the development of tolerance in vitro. MICs of both cloxacillin and vancomycin did not change significantly during this procedure. Whether the conversion of nontolerant strains to the tolerant state can also occur during antibiotic exposure in treatment of patients remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7843178     DOI: 10.1007/bf02276057

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

1.  Role of tolerance in cloxacillin prophylaxis of experimental Staphylococcus aureus endocarditis.

Authors:  G P Voorn; J Thompson; W H Goessens; W Schmall-Bauer; P H Broeders; M F Michel
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

2.  Production of Staphylococcus Strains Resistant to Various Concentrations of Penicillin.

Authors:  M Demerec
Journal:  Proc Natl Acad Sci U S A       Date:  1945-01       Impact factor: 11.205

3.  In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin.

Authors:  C Watanakunakorn
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Association of penicillin-tolerant streptococci with epidemics of streptococcal pharyngitis in closed communities.

Authors:  R Dagan; M Ferne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

5.  Significance of in-vitro penicillin tolerance in experimental enterococcal endocarditis.

Authors:  K S Kim; A S Bayer
Journal:  J Antimicrob Chemother       Date:  1987-04       Impact factor: 5.790

6.  Beta-lactam-specific resistant mutants of Staphylococcus aureus.

Authors:  E Tonin; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

7.  Therapeutic significance of penicillin tolerance in experimental streptococcal endocarditis.

Authors:  R O Brennan; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

8.  Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species.

Authors:  F Biavasco; E Giovanetti; M P Montanari; R Lupidi; P E Varaldo
Journal:  J Antimicrob Chemother       Date:  1991-01       Impact factor: 5.790

9.  A new type of penicillin resistance of Staphylococcus aureus.

Authors:  L D Sabath; N Wheeler; M Laverdiere; D Blazevic; B J Wilkinson
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

Review 10.  Antibiotic-resistant Streptococcus pneumoniae: clinical and epidemiologic aspects.

Authors:  J Ward
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr
View more
  2 in total

1.  Role of monocytes in experimental Staphylococcus aureus endocarditis.

Authors:  M H Veltrop; M J Bancsi; R M Bertina; J Thompson
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

2.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.